TSHA RSI Chart
Last 7 days
32.5%
Last 30 days
26.5%
Last 90 days
62.3%
Trailing 12 Months
342.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 14.2M | 0 | 0 | 0 |
2023 | 5.7M | 9.0M | 12.2M | 15.4M |
2022 | 0 | 0 | 0 | 2.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 02, 2024 | alam kamran | sold (taxes) | -1,944 | 1.51 | -1,288 | chief financial officer |
Jan 02, 2024 | alam kamran | acquired | - | - | 590,413 | chief financial officer |
Jan 02, 2024 | nagendran sukumar | acquired | - | - | 863,617 | president and head of r&d |
Jan 02, 2024 | nolan sean p. | acquired | - | - | 1,184,690 | chief executive officer |
Nov 17, 2023 | manning paul b | bought | 163,000 | 1.63 | 100,000 | - |
Aug 24, 2023 | alam kamran | sold | -76,890 | 2.33 | -33,000 | chief financial officer |
Aug 16, 2023 | manning paul b | bought | 14,820,000 | 0.9 | 16,466,700 | - |
Aug 16, 2023 | donenberg phillip b. | bought | 99,999 | 0.9 | 111,111 | - |
Aug 16, 2023 | nolan sean p. | bought | 400,000 | 0.9 | 444,444 | chief executive officer |
Aug 16, 2023 | stalfort john a iii | bought | 350,000 | 0.9 | 388,889 | - |
Which funds bought or sold TSHA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | added | 0.67 | 4,099,260 | 10,583,300 | 0.27% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 39.28 | 94,171 | 169,003 | -% |
May 15, 2024 | PRELUDE CAPITAL MANAGEMENT, LLC | reduced | -70.56 | -175,668 | 160,413 | 0.01% |
May 15, 2024 | MORGAN STANLEY | added | 2,287 | 14,451,400 | 14,834,700 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | reduced | -79.19 | -245,085 | 124,845 | 0.03% |
May 15, 2024 | Point72 Asset Management, L.P. | reduced | -58.59 | -1,562,780 | 3,194,980 | 0.01% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -99.99 | -4,066,110 | 566 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 1,168 | 2,891,470 | 3,039,220 | -% |
May 15, 2024 | Graham Capital Management, L.P. | sold off | -100 | -50,404 | - | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 2,957,990 | 2,957,990 | -% |
Unveiling Taysha Gene Therapies Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Taysha Gene Therapies Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Taysha Gene Therapies Inc News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 |
Revenue | -5.4% | 3,411 | 3,607 | 4,746 | 2,395 | 4,700 | 3,264 | 1,828 | 392 |
Operating Expenses | 39.8% | 27,741 | 19,850 | 20,996 | 25,779 | 21,265 | 56,468 | 25,457 | 33,373 |
S&GA Expenses | -100.0% | - | 6,719 | 8,589 | 5,988 | 8,751 | 7,341 | 8,683 | 9,867 |
R&D Expenses | 62.9% | 20,657 | 12,682 | 11,791 | 19,791 | 12,514 | 12,707 | 16,774 | 23,506 |
Interest Expenses | 86.4% | 1,329 | 713 | 1,471 | 1,440 | 1,374 | 1,305 | 1,078 | 743 |
Net Income | -150.4% | -24,061 | 47,741 | -117,087 | -24,598 | -17,622 | -55,078 | -26,527 | -34,092 |
Net Income Margin | -15.4% | -8.33* | -7.22* | -17.56* | -13.80* | -23.23* | -66.35* | - | - |
Free Cashflow | -23.6% | -19,938 | -16,134 | -17,949 | -18,719 | -24,085 | 12,403 | -30,830 | -41,216 |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | -11.4% | 153 | 173 | 196 | 82.00 | 102 | 126 | 111 | 142 | 166 | 214 | 241 | 242 | 243 | 259 | 279 | - |
Current Assets | -12.9% | 131 | 150 | 172 | 54.00 | 72.00 | 96.00 | 43.00 | 77.00 | 107 | 160 | 197 | 207 | 240 | 258 | 279 | 0.00 |
Cash Equivalents | -13.9% | 124 | 144 | 164 | 45.00 | 63.00 | 88.00 | 34.00 | 66.00 | 97.00 | 149 | 189 | 197 | 229 | 251 | 279 | - |
Net PPE | -1.3% | 11.00 | 11.00 | 11.00 | 14.00 | 15.00 | 15.00 | 64.00 | 61.00 | 55.00 | 51.00 | 41.00 | 34.00 | 2.00 | 0.00 | 0.00 | - |
Liabilities | 1.4% | 99.00 | 98.00 | 245 | 119 | 117 | 125 | 100 | 110 | 115 | 119 | 101 | 55.00 | 20.00 | 8.00 | 12.00 | - |
Current Liabilities | 5.1% | 39.00 | 37.00 | 180 | 51.00 | 54.00 | 63.00 | 33.00 | 43.00 | 49.00 | 52.00 | 43.00 | 28.00 | 19.00 | 7.00 | 12.00 | 0.00 |
Long Term Debt | 0.0% | 41.00 | 41.00 | 39.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 37.00 | 37.00 | 28.00 | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 41.00 | 39.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 37.00 | 37.00 | 28.00 | - | - | - | - | - |
Shareholder's Equity | -28.1% | 54.00 | 75.00 | - | - | -14.95 | 1.00 | 11.00 | 33.00 | 51.00 | 95.00 | 140 | 186 | 223 | 251 | 268 | - |
Retained Earnings | -4.7% | -537 | -513 | -560 | -443 | -419 | -401 | -345 | -319 | -285 | -235 | -185 | -134 | -93.15 | -61.13 | -42.81 | -1.11 |
Additional Paid-In Capital | 0.5% | 591 | 588 | 512 | 407 | 404 | 402 | 357 | 352 | 336 | 331 | 326 | 321 | 316 | 312 | 310 | 1.00 |
Shares Outstanding | 0.0% | 187 | 187 | 187 | 64.00 | 63.00 | 63.00 | 40.00 | 40.00 | 38.00 | 38.00 | 37.00 | 37.00 | 37.00 | - | - | - |
Float | - | - | - | - | 30.00 | - | - | - | 92.00 | - | - | - | 479 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Cashflow From Operations | -22.8% | -19,798 | -16,117 | -17,949 | -18,767 | -20,185 | 14,712 | -28,810 | -33,353 | -40,939 | -40,258 | -31,933 | -22,816 | -22,035 | -19,848 | -6,716 | -2,466 | -1,699 | - | - |
Share Based Compensation | 62.5% | 3,198 | 1,968 | 2,040 | 2,222 | 1,675 | 4,103 | 4,470 | 4,141 | 5,329 | 4,955 | 5,086 | 4,549 | 3,594 | 2,013 | 1,341 | - | - | - | - |
Cashflow From Investing | -1300.0% | -140 | -10.00 | -3,490 | 48.00 | -3,900 | -2,370 | -3,020 | -8,113 | -11,427 | -8,520 | -4,002 | -8,498 | -534 | -6,051 | -31.00 | -3,000 | - | - | - |
Cashflow From Financing | 99.5% | -22.00 | -4,248 | 140,634 | 377 | -370 | 41,232 | -103 | 11,075 | -107 | 9,105 | - | - | - | -1,482 | 274,181 | 338 | 18,027 | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 3,411 | $ 4,706 |
Operating expenses: | ||
Research and development | 20,657 | 12,514 |
General and administrative | 7,084 | 8,751 |
Total operating expenses | 27,741 | 21,265 |
Loss from operations | (24,330) | (16,559) |
Other income (expense): | ||
Change in fair value of warrant liability | (337) | |
Change in fair value of term loan | (1,053) | |
Interest income | 1,693 | 319 |
Interest expense | (29) | (1,374) |
Other expense | (5) | (8) |
Total other income (expense), net | 269 | (1,063) |
Net loss | $ (24,061) | $ (17,622) |
Net loss per common share, basic | $ (0.1) | $ (0.28) |
Net loss per common share, diluted | $ (0.1) | $ (0.28) |
Weighted average common shares outstanding, basic | 231,249,344 | 63,260,905 |
Weighted average common shares outstanding, diluted | 231,249,344 | 63,260,905 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 123,980 | $ 143,940 |
Restricted cash | 449 | 449 |
Prepaid expenses and other current assets | 4,168 | 3,479 |
Assets held for sale | 2,000 | 2,000 |
Total current assets | 130,597 | 149,868 |
Restricted cash | 2,151 | 2,151 |
Property, plant and equipment, net | 10,686 | 10,826 |
Operating lease right-of-use assets | 9,261 | 9,582 |
Other non-current assets | 304 | 304 |
Total assets | 152,999 | 172,731 |
Current liabilities | ||
Accounts payable | 10,380 | 6,366 |
Accrued expenses and other current liabilities | 13,562 | 12,284 |
Deferred revenue | 14,695 | 18,106 |
Total current liabilities | 38,637 | 36,756 |
Term loan, net | 40,512 | 40,508 |
Operating lease liability, net of current portion | 18,499 | 18,953 |
Other non-current liabilities | 1,502 | 1,577 |
Total liabilities | 99,150 | 97,794 |
Commitments and contingencies - Note 13 | ||
Stockholders' (deficit) equity | ||
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 187,018,275 and 186,960,193 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 2 | 2 |
Additional paid-in capital | 591,166 | 587,942 |
Accumulated other comprehensive loss | (251) | |
Accumulated deficit | (537,068) | (513,007) |
Total stockholders' equity | 53,849 | 74,937 |
Total liabilities and stockholders' equity | $ 152,999 | $ 172,731 |